Similarly, other studies have identified the TGF-β pathway as a target for an anti-cancer pharmacological approach, particularly concerning the role of TGF-β in mediating the immunosuppression of immune cells and promoting angiogenesis and EMT in cancer cells [4]. The gene discussed is TGFB1; the disease is cancer.